Re-differentiation of Radioiodine-Refractory BRAF V600E-mutant Papillary Thyroid Carcinoma With GSK2118436

NCT01534897 · clinicaltrials.gov ↗

NA

Phase

COMPLETED

Status

10

Enrollment

OTHER

Sponsor class

Conditions

Papillary Thyroid Carcinoma

Interventions

DRUG: GSK2118436

Sponsor

Massachusetts General Hospital

Collaborators

[object Object]